Journal of Neuro-Oncology

, Volume 4, Issue 1, pp 5–16

Apparent glucose utilization in Walker 256 metastatic brain tumors

  • Ronald G Blasberg
  • Mami Shinohara
  • William R Shapiro
  • Clifford S Patlak
  • Karen D Pettigrew
  • Joseph D Fenstermacher


Regional rates of apparent glucose utilization (GU) in metastatic Walker 256 (WL-256) brain tumors produced by the intracarotid injection of WL-256 tumor cells in rats were measured using14C-deoxyglucose and quantitative aroradiography. Apparent glucose utilization was uniform within individual small and medium size tumors without necrosis, varied considerably among different tumors within this group, and did not correlate with tumor size or location. High values of GU in medium and large-size tumors correlated with viable-appearing tissue in contrast to necrotic tissue and were always 1.3 to 3 times higher than that of adjacent and contralateral nontumorous brain. The apparent net extraction of glucose (En*) in viable tumor regions was estimated to be several fold higher than that in remote brain tissue; analysis of this data for medium and large tumors indicates that the calculated values of GU and En* overestimate the actual rates of utilization and net extraction of glucose. Local cerebral glucose utilization (LCGU) was higher than normal adjacent to small tumors and lower than normal adjacent to large tumors. The LCGU in many gray-matter structures remote from the intracerebral tumors was reduced and roughtly proportional to the metastatic tumor burden. The comparatively high uptake of 2-deoxyglucose by viable tumor cells has diagnostic and localization value and suggests that appropriate glucose analogues could be developed to produce a tumor-selective inhibition of glycolysis and tumoricidal effect.

Key words

glucose utilization Walker 256 tumors metastatic brain tumors deoxyglucose quantitative autoradiography 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Warburg O: The Matabolism of Tumors. London, Constable and Co., 1930, pp 327.Google Scholar
  2. 2.
    Viale GL: Biochemical patterns in brain tumors. I. Enzymes of the glycolysis. Acta Neurochirurg 20: 263–272, 1969.CrossRefGoogle Scholar
  3. 3.
    Kirsh WM, Shultz D, Van Buskirk J., Nakane P: Anerobic energy metabolism in brain tumors. In Bingham WG (ed): Recent Advances in Brain Tumor Research. Prog Exp Tumo Res 17, Basel, Karger, 1972 pp 163–191.Google Scholar
  4. 4.
    Allen N: Oxidative metabolism of brain tumors. In Bigham WG (ed): Recent Advances in Brain Tumor Research. Prog Exp Tumor Res 17, Basel, Karger, 1972, pp 192–209.Google Scholar
  5. 5.
    Wollman M: Biochemistry of brain tumors. In Lajtha A (ed): Handbook of Neurochemistry. New York, Plenum Press, 1972, vol 7, pp 503–542.Google Scholar
  6. 6.
    Himwich HE: Brain Metabolism and Cerebral Disorders. Baltimore, Williams and Wilkens, 1951.Google Scholar
  7. 7.
    McIlwain HH: Biochemistry of the Central Nervous System. London, Churchill, 1966.Google Scholar
  8. 8.
    Siesjo BK: Brain Energy Metabolism. London, Wiley, 1978.Google Scholar
  9. 9.
    Wassenaar W, Tator CH: Glucose analogues as potential agents for brain tumor diagnosis and treatment. Trans Am Neurol Assoc 98: 43–48, 1973.PubMedGoogle Scholar
  10. 10.
    Wassenaar W, Tator CH, Batty HP: Glucose analogs as potential diagnostic tracers for brain tumors. Cancer Res 35: 785–790, 1975.PubMedGoogle Scholar
  11. 11.
    DiChiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kufta CV, Kessler RM, Johnston GS, Manning RG, Wolf AP: Glucose utilization of cerebral gliomas measured by [18F]fluorodeoxyglucose and positron emission tomogrpahy. Neurology 32: 1323–1329, 1982.PubMedGoogle Scholar
  12. 12.
    DiChiro G, Brooks RA, Sokoloff L, Patronas NJ, DeLaPaz RL, Smith BH, Kornblith PL: Glycolytic rate and histologic grade of human cerebral gliomas: a study with (18F)fluorodeoxyglucose and postron emission tomography. In Heiss W-D and Phelps ME (eds): Positron Emission Tomography of the Brain. Berlin, Springer-Verlag, 1983, pp 181–191.Google Scholar
  13. 13.
    Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M: The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 28: 897–916, 1977.PubMedGoogle Scholar
  14. 14.
    Goochee C, Rasband W, Sokoloff L: Computerized densitometry and color coding of14C-deoxyglucose autoradiography. Ann Neurol 7: 359–370, 1980.CrossRefPubMedGoogle Scholar
  15. 15.
    Blasberg RG, Shapiro WR, Molnar P, Patlak CS, Fenstermacher JD: Local blood flow in Walker 256 metastatic brain tumors. J Neurooncol 2: 195–204, 1984.PubMedGoogle Scholar
  16. 16.
    Sokoloff HB, Eddy WH, Saelholf CC, Beach J: Glucose antagonists in experimental cancer. Arch Pathol Lab Med 59: 729–732, 1955.Google Scholar
  17. 17.
    Ball HA, Wick AN, Sanders C: Influence of glucose antimetabolites on the Walker tumor. Cancer Res 17: 235–239, 1957.PubMedGoogle Scholar
  18. 18.
    Laszlo J, Humphreys SR, Goldin A: Effects of glucose analogs (2-deoxy-D-glucose, 2-deoxy-D-galactose) on the experimental tumors. J Natl Cancer Inst 24: 267–281, 1960.PubMedGoogle Scholar
  19. 19.
    Cummulative drug screening data on D-glucose, 2-deoxy-(NSC 015193); Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20205.Google Scholar
  20. 20.
    Tannock IF, Guttman P, Rauth AM: Failure of 2-deoxy-D-glucose and 5-thio-D-glucose to kill hypoxic cells of two murine tumors. Cancer Res. 43: 980–983, 1983.PubMedGoogle Scholar
  21. 21.
    Ushio Y, Chernik NL, Shapiro WR, Posner J: Metastatic tumor of the brain: development of an experimental model. Ann Neurol 2: 20–29, 1977.CrossRefPubMedGoogle Scholar
  22. 22.
    Sokoloff L: The [14C] deoxyglucose method: four years later. Acta Neurol Scand Suppl 60: 640–649, 1979.Google Scholar
  23. 23.
    Graham MM, Spence AM, Larson SM: Glucose metabolic rates in transplanted astrocytic gliomas in rats. J Cereb Blood Flow Metab 3 (Supplement 1): S41-S42, 1983.Google Scholar
  24. 24.
    Suda S, Shinohara M, Miyaoka M, Kennedy C, Sokoloff L: Local cerebral glucose utilization in hypoglycemia. J Cereb Blood Flow Metabol 1 (Supplement 1): S62, 1981.Google Scholar
  25. 25.
    Paschen W, Mies G, Bodsch W, Hossmann K-A: Regional multiparametric assessment of brain tumors and brain infarcts. In Meyer JS, Lechner H, Reivich M, Ott EO (eds.): Cerebral Vascular Disease IV, Amsterdam, Excerpta Medica, 1982, pp 86–90.Google Scholar
  26. 26.
    Sokoloff L: The radioactive deoxyglucose method. In Agranoff BW, Aprinson MH (eds.): Advances in Neurochemistry, Vol. 4. New York, Plenum Publishing Corp., 1982, pp 1–82.Google Scholar
  27. 27.
    LeFevre PG: Transport of carbohydrates by animal cells. In Hokin L (ed): Metabolic Pathways; Metabolic Transport; Vol. 6. New York, Academic Press, 1972, pp 358–454.Google Scholar
  28. 28.
    Crone C: Fascilitated transfer of glucose from blood into brain tissue. J Physiol (London) 181: 103–113, 1965.Google Scholar
  29. 29.
    Pardridge WM, Oldendorf WH: Kinetics of blood-brain barrier transport of hexoses. Biochem Biophys Acta 382: 377–392, 1975.PubMedGoogle Scholar
  30. 30.
    Gjedde A: Rapid steady-state analysis of blood-brain glucose transfer in rat. Acta Physiol Scand 108: 331–339, 1980.PubMedGoogle Scholar
  31. 31.
    Blasberg RG, Kobayashi T, Patlak CS, Shinohara M, Miyaoka M, Rice JM, and Shapiro WR: Regional blood flow, capillary permeability, and glucose utilization in two brain tumor models: preliminary observations and pharmacokinetic implications. Cancer Treat Rep 65 (Supplement 2): 3–12, 1981.Google Scholar
  32. 32.
    Blasberg RG, Gazendam J, Shapiro W, Shinohara M, Patlak CS, and Fenstermacher J: Clinical implications of quantitative autoradiographic measurements of regional blood flow, capillary permeability and glucose utilization in a metastatic brain tumor model. In Hildebrand J, Gangji D (eds): Treatment of Neopplastic Lesions of the Nervous System, Oxford, Pergamon Press Ltd, 1982, pp 135–141.Google Scholar
  33. 33.
    Weber G: Enzymology of cancer cells. II. N Engl J Med 296: 541–551, 1977.PubMedGoogle Scholar
  34. 34.
    Timperly WR: Glycolysis in neuroectodermal tumours. In Thomas DGT, Graham DI (eds): Brain Tumours. London, Butterworth, 1980, pp 145–167.Google Scholar
  35. 35.
    Yamada K, Ushio Y, Hayakawa T, Arita N, Yamada N, Mogami H: Effects of methylprednisolone on peritumoral brain edema. J Neurosurg 59: 612–619, 1983.PubMedGoogle Scholar
  36. 36.
    Blasberg RG, Molnar P, Groothuis D, Patlak CS, Fenstermacher J: Simultaneous measurements of blood flow and relative glucose utilization in ASV induced brain tumors. J Cereb Blood Flow Metabol. 1 (Supplement 1): 568, 1981.Google Scholar
  37. 37.
    Hossmann K-A, Niebuhr I, Tamara M: Local cerebral blood flow and glucose consumption of rats with experimental gliomas. J Cereb Blood Flow Metabol. 2: 25–32, 1982.Google Scholar
  38. 38.
    Kirsch WM, Tucker WS, Tabuchi K, Fink LM, van Buskirk J, Low M: The metabolism of the glioblastoma: pathological correlates. Clin Neurosurg 25: 310–325, 1978.PubMedGoogle Scholar
  39. 39.
    Pettigrew KD, Sokoloff L, Patlak CS: A theoretical derivation of the lumped constant for the 2-deoxyglucose method for measuring local glucose metabolism in the brain. J Cereb Blood Flow Metabol. 3 (Supplement 1): S89-S90, 1983.Google Scholar
  40. 40.
    Crane PD, Pardridge WM, Braun LD, Nyerges AM, Oldendorf WH: The interaction of transport and metabolism on glucose utilization: reevaluation of the lumped constant. J Neurochem 36: 1601–1604, 1981.PubMedGoogle Scholar
  41. 41.
    Gjedde A: Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-exaination. Brain Research Reviews 4: 237–274, 1982.CrossRefGoogle Scholar
  42. 42.
    Gjedde A, Wienhard K, Heiss W-D, Kloster G, Diemer NH, Herholz K, Pawlik G: Comparative regional analysis of 2-fluorodeoxyglucose and methylglucose uptake in brain of four stroke patients. J Cereb Blood Flow Metabol. 5: 163–178, 1985.Google Scholar
  43. 43.
    Rhodes CG, Wise RJS, Gibbs JM, Frackowiak RSJ, Hatazawa J, Palmer AJ, Thomas DGT, Jones T: In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann Neurol 14: 614–626, 1983.CrossRefPubMedGoogle Scholar
  44. 44.
    Di Chiro G, Brooks RA, Patronas NJ, Bairamian D, Kornblith PL, Smith BH, Mansi L, Barker J: Issues in the in vivo measurement of glucose metabolism of human central nervous system tumors. Ann Neurol 15 (suppl): S138-S146, 1984.CrossRefPubMedGoogle Scholar
  45. 45.
    Tower DB: The effects of 2-deoxy-D-glucose on metabolism of slices of cerebral cortex incubated in vitro. J Neurochem 3: 185–205, 1958.PubMedGoogle Scholar
  46. 46.
    Landau BR, Lubs HA: Animal responses to 2-deoxy-D-glucose administration. Proc Soc Exp Biol (NY) 99: 124–127, 1958.Google Scholar
  47. 47.
    Horton RW, Meldrum BS, Bachelard HS: Enzymic and cerebral metabolic effects of 2-deoxy-D-glucose. J Neurochem 21: 507–520, 1973.PubMedGoogle Scholar
  48. 48.
    Frey KA, Agranoff BW: Barbiturate-enhanced detection of brain lesions by carbon-14-labeled 2-deoxyglucose autoradiography. Science 219: 879–881, 1983.PubMedGoogle Scholar
  49. 49.
    Kendall MG, Stuart A: The Advanced Theory of Statistics; Vol. I, Distribution Theory. Wagner Publ. Co., NY, 1958, pp 231.Google Scholar
  50. 50.
    Sakurada O, Kennedy C, Jehle J, Brown JD, Carbin GL, Sokoloff L: Measurement of local cerebral blood flow with lodo (14C)-antipyrine. Am J Physiol 234(1): H59-H66, 1978.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers 1986

Authors and Affiliations

  • Ronald G Blasberg
    • 1
  • Mami Shinohara
    • 2
    • 1
  • William R Shapiro
    • 3
    • 1
  • Clifford S Patlak
    • 4
    • 1
  • Karen D Pettigrew
    • 4
    • 1
  • Joseph D Fenstermacher
    • 1
  1. 1.Laboratory of Medicinal Chemistry and Pharmacology, Division of Cancer TreatmentNational Cancer InstituteBethesda
  2. 2.Laboratory of Cerebral Metabolism, National Institute of Mental HealthNIHBethesda
  3. 3.Department of NeurologyMemorial Sloan-Kettering Cancer Center and Cornell UniversityNew York
  4. 4.Theoretical Statistics and Mathematics Branch, National Institute of Mental HealthNIHBethesda
  5. 5.Department of Neurological Surgery, Health Sciences Center, T12-082State University of New York at Stony BrookStony Brook
  6. 6.Nuclear Medicine Department, CCNational Institutes of HealthBethesda

Personalised recommendations